Security record · archived quarter
ENTA
Enanta Pharmaceuticals, Inc. · Healthcare · Biotechnology
1Tracked holders
0Δ holders
11.84KShares held
$143,216Reported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 11.84K | $143,216 | n/a | n/a |
| Q2 2026 | 56 | -3 | 10.74M | $156.55M | +2 | −5 |
| Q1 2026 | 62 | -2 | 14.86M | $187.69M | +5 | −7 |
| Q4 2025 | 64 | +3 | 16.10M | $253.79M | +3 | n/a |
| Q3 2025 | 16 | +1 | 7.96M | $95.31M | +2 | −1 |
| Q2 2025 | 12 | 0 | 8.38M | $63.38M | n/a | n/a |
| Q1 2025 | 9 | -2 | 4.49M | $24.81M | n/a | −2 |
| Q4 2024 | 11 | -1 | 4.05M | $23.26M | n/a | −1 |
| Q3 2024 | 11 | +2 | 4.15M | $43.00M | +2 | n/a |
| Q2 2024 | 9 | n/a | 3.87M | $50.19M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 11.84K | -11.1% | $143,216 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 131 holders, 26.72M shares, $290.62M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 14
SC 13G/A: FARALLON CAPITAL MANAGEMENT, L.L.C.
Aug 14
SC 13G/A: Deep Track Capital, LP
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API